At Conversant Bio we offer a wide variety of fresh and frozen human primary cells that can target virtually any disease, stage or grade with detailed patient annotation. From peripheral blood, bone marrow, processed and whole tissue, xenograft tumor cells, and other human biospecimens, we can meet your research needs.
Most autoimmune disease research revolves around understanding the nuances of diseases in order to develop potential treatment options. High quality biospecimens are an important part of this work.
Autoimmune disease biospecimens open up possibilities to advance immunology research through sample specificity and flexibility. Downlaod this free ebook and learn research discoveries and challenges, auto-immune treatments and medications and more!
A leader in developing a new treatment for castrate resistant prostate cancer (CRPC), this pharmaceutical company needed access to samples from patients with Stage IV CRPC. Acquiring these samples was complicated by the fact that they needed them shipped to an overseas facility within an extremely tight deadline.
Conversant Bio has a vast U.S. based collection network in place to procure samples for prospective projects like this one.
We have worked with hundreds of researchers and scientists to provide them with the highest quality primary human specimens available anywhere. We want to make the challenges associated with obtaining high quality biospecimens a thing of the past.
We believe that a reliable sourcing partner is essential to groundbreaking research and drug discovery. Our team is available to help you find samples to match your specific project’s parameters.
"The rate limiting step in our research into human disease is access to high-quality, well-characterized tissues. Conversant Bio is an incredible resource that has come along at the right time; their specimens are opening doors to research we never imagined possible in years past."
Rick Myers, PhD, President and Director, HudsonAlpha Institute
"We need good quality samples so that we can understand the expression of our drug targets, to identify whether or not the drug is working in the manner we expect it to."
Scott Patterson, PhD, Executive Director, Amgen, Inc.
It can cost up to $4 billion and take, on average, 12 years to bring a new drug to market. One of the biggest challenges for R&D is improving the early clinical discovery steps, so that...Read More
Advancements in molecular analysis and pathology methods have been striking over the past decade, and one reason is the discovery that archival formalin-fixed paraffin-embedded (FFPE) tissue...Read More
Colorectal cancer (CRC) is the third most common cancer worldwide and in the U.S. Because it is increasing in incidence and is often diagnosed late, there is great urgency for good models to study...Read More
By some estimates, there are more than one billion formalin-fixed paraffin embedded (FFPE) tissue specimens preserved in tissue archives around the world. These specimens are invaluable resources for...Read More